SIEMENS has formed a partnership with process plant designer Exyte to quickly deliver turnkey biopharmaceutical manufacturing plants.
The collaboration comes amid the Covid-19 pandemic as companies and countries seek to develop treatments and then produce them at scale. The chemical engineering community has been discussing the challenges of manufacturing new treatments at scale in the time required, noting that existing production sites tend not to sit idle and cannot be requisitioned without disrupting the supplies of other treatments.
Siemens and Exyte are offering standardised, modular, turnkey facilities embedded with Siemens’ process automation technology that comply with cGMP (current Good Manufacturing Practice) and GAMP (Good Automated Manufacturing Practice) to biotechnology manufacturers as well as cell and gene therapy manufacturers.
They say the first such buildings are already being designed for use in China and Europe.
Catch up on the latest news, views and jobs from The Chemical Engineer. Below are the four latest issues. View a wider selection of the archive from within the Magazine section of this site.